ArticleLasers in medical science2026
Effects of photobiomodulation, alone or combined with dexamethasone, on cellular metabolic activity and inflammatory markers in LPS/IFN-γ-stimulated J774 macrophages.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the effects of photobiomodulation (PBM), dexamethasone (DEXA), and their combination on cellular metabolic activity and inflammatory cytokines in LPS/IFN-γ-stimulated J774 macrophages.Cells were stimulated with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ) and treated with PBM (780 nm) and/or DEXA (2 or 4 μM). Cellmorphology, metabolic activity assessed by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and total protein, tumornecrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) levels measured by enzyme-linked immunosorbent assay (ELISA) were analyzed at 24 and 48hours. PBM combined with DEXA at 2 μM increased MTT metabolic activity at 24 hours and was associated with preserved morphology and maintainedhigher total protein levels, with consistent superiority over DEXA alone. PBM + DEXA 2 μM produced the strongest reduction in TNF-α and IL-6 at 24hours, and IL-6 levels remained lower at 48 hours compared to the M1 + PBM group. The 4 μM dose demonstrated lower efficacy and signs of functionalimpairment, which were partially mitigated by PBM. These findings indicate that PBM may enhance the anti-inflammatory effects of low-dose DEXA while supporting a favorable cellular metabolic response, suggesting its potential as an adjunct strategy to optimize the glucocorticoid-based modulation ofinflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.